XBITNasdaqPharmaceutical PreparationsFiscal year ends December 31
XBiotech Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.00−0.12 (-5.66%)
Close on Oct 19, 2026
- Market cap
- $60.98M
- P/E (TTM)
- –
- Dividend yield
- –
XBiotech Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Manufacturing Revenue [Member] | $4.01M | $18.00M | $18.00M | $0 | $0 | 100.0% | -77.7% |
| Clinical Trial Service Revenue [Member] | $0 | $394.00K | $25.98M | $0 | $0 | 0.0% | -100.0% |
| Product and Service, Other [Member] | – | $0 | $22.00K | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of XBiotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.